Peptide PilotPeptide Pilot
Download on the App Store

Comparison

Ipamorelin vs GHRP-6

Selective ipamorelin next to GHRP-6 — appetite response and side-effect notes are the most-tracked differences.

Download on the App StoreiPhone · Free to download
Field
Ipamorelin
GHRP-6
Category
GH Secretagogue
GH Secretagogue
Common alias
—
—
Example vial
2 mg + 2 mL BAC water
5 mg + 2 mL BAC water
Concentration
1.00 mg/mL
2.50 mg/mL
Example dose
0.2 mcg
0.1 mcg
Doses per week
7× / week
7× / week
Doses per vial (rounded down)
10
50
Approx vial duration
1.4 weeks
7.1 weeks

Ipamorelin and GHRP-6 both show up in the same conversations, but they aren't interchangeable. The table above lays the vial math side by side so you can see how concentration, doses-per-vial, and weekly cadence actually compare. The sections below walk through what each one is, how each is studied, and how each shows up in a tracked log — in plain English, no recommendations.

Tiebreakers

Where Ipamorelin and GHRP-6 actually diverge

IpamorelinGHRP-6
Cadence7/wk7/wk
Concentration on example1.00 mg/mL2.50 mg/mL
Math weeks per vial1.47.1
CategoryGH SecretagogueGH Secretagogue

Bolded values are the higher of the two on numeric rows. Same-value rows aren't a verdict — they're shared properties.

Ipamorelin vs GHRP-6: the actual decision

The defining contrast between these two ghrelin-mimetics is appetite response. Ipamorelin is selective enough that most logs do not show a meaningful change in hunger after an administration. GHRP-6, on the other hand, produces a sharp appetite stimulus within thirty to sixty minutes for the majority of users — strong enough that the protocol calendar usually has to be planned around it. That single difference is the reason most modern stacks default to ipamorelin and only reach for GHRP-6 when the appetite stimulus is itself a desired effect.

GH-release potency is the other main axis. GHRP-6 produces a larger acute GH pulse than ipamorelin at equivalent per-dose milligrams; the trade is the appetite signal plus modest movement on cortisol and prolactin that ipamorelin avoids. For a log that is trying to isolate the GH signal from every other variable, ipamorelin is the cleaner choice. For a log that includes appetite as a deliberate variable — recomposition cycles, for example — GHRP-6 makes the signal easier to read.

Mechanism, cadence, and what shows up in a log

Cadence is similar between the two molecules: short half-lives drive two-to-three administrations a day in most protocols. Per-dose milligrams are usually 100 mcg for ipamorelin and 100–150 mcg for GHRP-6. The unit math on a 100-unit syringe at the same vial concentration lands in the same range, but the per-day total milligrams is slightly different because of the dose difference. The vial-duration calculator linked below shows how that difference compounds across a month.

Stack pairing reads quite differently between the two. Ipamorelin pairs most often with a GHRH-side peptide like CJC-1295 or sermorelin to push GH from both ends of the pathway. GHRP-6 also pairs that way, but the appetite signal usually wants its own log field so the stack data does not get muddied. Either molecule reconstitutes identically and is administered with the same insulin syringe geometry.

Ipamorelin vs GHRP-6: the numbers, side by side

Start with what actually goes into a syringe. The example Ipamorelin vial on this site reconstitutes 2 mg in 2 mL of bacteriostatic water — about 1.00 mg per mL, which yields roughly 10 doses at the 200 mcg example and lasts about 1.4 weeks at 7 doses per week. The example GHRP-6 vial reconstitutes 5 mg in 2 mL (2.50 mg/mL), which yields about 50 doses at 100 mcg and stretches roughly 7.1 weeks at 7 doses per week. Those numbers are the starting point most people forget to write down, and they decide everything downstream — refill timing, unit count on the syringe barrel, and whether a 30-mL bac-water bottle stretches across one vial or two.

Category context matters too. Both Ipamorelin and GHRP-6 sit in the GH Secretagogue bucket, so the head-to-head questions readers bring here are usually about cadence, titration step size, and which of the two molecules logs more cleanly inside a longer protocol rather than a from-scratch category choice. Cadence helps frame the rest: Ipamorelin is logged about 7× per week in the example schedule, GHRP-6 about 7×.

The single most-asked-about mistake on each page is worth surfacing here, because they rarely overlap. On the Ipamorelin side: Administering doses at inconsistent times of day, which compromises the ability to observe long-term trends related to its selective action. On the GHRP-6 side: Failing to document the potent hunger response on a consistent scale, mistaking a primary mechanistic effect for an incidental side effect. Both are the kind of thing a tracked log catches early and an untracked routine catches late.

Top Ipamorelin question
What is the primary distinction between Ipamorelin and GHRP-6?

The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.

Top GHRP-6 question
How does tracking for GHRP-6 differ from tracking for ipamorelin or GHRP-2?

The primary distinction is the emphasis on appetite monitoring. A log for ipamorelin would focus almost exclusively on GH-related metrics, whereas a log for GHRP-6 should feature a hunger rating (e.g., on a 1–10 scale) as a primary data field. Because GHRP-6 binds to the ghrelin receptor in a manner that strongly stimulates appetite, this orexigenic effect is a direct part of its mechanism to be observed, not a secondary consideration.

The calculator pages linked below let you swap your own vial size, diluent volume, and dose into the same math — these example numbers exist so the comparison renders with concrete figures instead of placeholders.

Frequently asked questions about Ipamorelin vs GHRP-6

What is the primary distinction between Ipamorelin and GHRP-6?
The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.
Why is Ipamorelin often studied in combination with CJC-1295 without DAC?
This combination is studied because it targets two separate pituitary receptors to synergistically amplify GH release. Ipamorelin acts on the ghrelin receptor while CJC-1295 (no DAC) acts on the GHRH receptor. Activating both pathways at once generates a more robust GH pulse than using either peptide alone, while still honoring the body's natural pulsatile rhythm.
How many units are required for a 200 mcg dose from a 2 mg vial reconstituted with 2 mL?
A 2 mg vial holds 2,000 micrograms of peptide. When reconstituted with 2 mL of bacteriostatic water, the final concentration becomes 1,000 mcg per mL. To draw a 200 mcg dose, you need 0.2 mL of the solution, which measures as exactly 20 units on a U-100 insulin syringe.
How does tracking for GHRP-6 differ from tracking for ipamorelin or GHRP-2?
The primary distinction is the emphasis on appetite monitoring. A log for ipamorelin would focus almost exclusively on GH-related metrics, whereas a log for GHRP-6 should feature a hunger rating (e.g., on a 1–10 scale) as a primary data field. Because GHRP-6 binds to the ghrelin receptor in a manner that strongly stimulates appetite, this orexigenic effect is a direct part of its mechanism to be observed, not a secondary consideration.
What do historical research studies indicate about cortisol and prolactin with GHRP-6?
Scientific literature dating back to the 1980s consistently shows that GHRP-6 administration leads to measurable, dose-dependent increases in plasma cortisol and prolactin. This effect is significantly more pronounced than that observed with its successors, GHRP-2 and ipamorelin. In fact, the desire to reduce these off-target hormonal effects was a major driver behind the development of those later-generation peptides.
If a 5 mg vial is prepared with 2 mL of diluent, how many units is a 100 mcg dose?
With 5 mg (or 5,000 mcg) of peptide dissolved in 2 mL of diluent, the solution's concentration becomes 2,500 mcg/mL. A U-100 syringe contains 100 units per mL, meaning each single unit delivers 25 mcg of peptide (2,500 mcg ÷ 100 units). To calculate the volume for a 100 mcg dose, one would divide the target dose by the per-unit concentration (100 mcg ÷ 25 mcg/unit), which results in a required volume of 4 units.

Related on Peptide Pilot

Log Ipamorelin and GHRP-6 side by side in the app

Download on the App StoreiPhone · Free · No credit card
Download on theApp Store→